<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Vasc Med</journal-id><journal-id journal-id-type="iso-abbrev">Vasc Med</journal-id><journal-id journal-id-type="publisher-id">VMJ</journal-id><journal-id journal-id-type="hwp">spvmj</journal-id><journal-title-group><journal-title>Vascular Medicine (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1358-863X</issn><issn pub-type="epub">1477-0377</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7306998</article-id><article-id pub-id-type="doi">10.1177/1358863X20932640</article-id><article-id pub-id-type="publisher-id">10.1177_1358863X20932640</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><?covid19?>COVID-19-associated coagulopathy: An exploration of
mechanisms</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Colling</surname><given-names>Meaghan E</given-names></name><xref ref-type="aff" rid="aff1-1358863X20932640">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5660-5194</contrib-id><name><surname>Kanthi</surname><given-names>Yogendra</given-names></name><xref ref-type="aff" rid="aff2-1358863X20932640">2</xref><xref ref-type="corresp" rid="corresp1-1358863X20932640"/></contrib></contrib-group><aff id="aff1-1358863X20932640"><label>1</label>Division of Intramural Research,
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda,
MD, USA</aff><aff id="aff2-1358863X20932640"><label>2</label>Department of Internal Medicine,
Division of Cardiovascular Medicine, University of Michigan, and Ann Arbor Veterans
Administration Healthcare System, Ann Arbor, MI, USA</aff><author-notes><corresp id="corresp1-1358863X20932640">Yogendra Kanthi, Department of Internal
Medicine, Division of Cardiovascular Medicine, University of Michigan, and Ann
Arbor Veterans Administration Healthcare System, 2344 Cardiovascular Center,
1500 E Medical Center Dr. SPC 5856, Ann Arbor, MI 48109-5856, USA. Email:
<email>ykanthi@umich.edu</email> Twitter: <ext-link ext-link-type="uri" xlink:href="https://twitter.com/yogenkanthi">@yogenkanthi</ext-link></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>6</month><year>2020</year></pub-date><elocation-id>1358863X20932640</elocation-id><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits
any use, reproduction and distribution of the work without further
permission provided the original work is attributed as specified on the SAGE
and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p>An ongoing global pandemic of viral pneumonia (coronavirus disease [COVID-19]),
due to the virus SARS-CoV-2, has infected millions of people and remains a
threat to many more. Most critically ill patients have respiratory failure and
there is an international effort to understand mechanisms and predictors of
disease severity. Coagulopathy, characterized by elevations in D-dimer and
fibrin(ogen) degradation products (FDPs), is associated with critical illness
and mortality in patients with COVID-19. Furthermore, increasing reports of
microvascular and macrovascular thrombi suggest that hemostatic imbalances may
contribute to the pathophysiology of SARS-CoV-2 infection. We review the
laboratory and clinical findings of patients with COVID-19-associated
coagulopathy, and prior studies of hemostasis in other viral infections and
acute respiratory distress syndrome. We hypothesize that an imbalance between
coagulation and inflammation may result in a hypercoagulable state. Although
thrombosis initiated by the innate immune system is hypothesized to limit
SARS-CoV-2 dissemination, aberrant activation of this system can cause
endothelial injury resulting in loss of thromboprotective mechanisms, excess
thrombin generation, and dysregulation of fibrinolysis and thrombosis. The role
various components including neutrophils, neutrophil extracellular traps,
activated platelets, microparticles, clotting factors, inflammatory cytokines,
and complement play in this process remains an area of active investigation and
ongoing clinical trials target these different pathways in COVID-19.</p></abstract><kwd-group><kwd>anticoagulation</kwd><kwd>antiplatelet</kwd><kwd>coagulation</kwd><kwd>coronavirus</kwd><kwd>COVID-19</kwd><kwd>inflammation</kwd><kwd>NETs</kwd><kwd>neutrophils</kwd><kwd>thrombosis</kwd><kwd>vascular endothelium</kwd><kwd>venous thromboembolism (VTE)</kwd></kwd-group><funding-group><award-group id="award1-1358863X20932640"><funding-source id="funding1-1358863X20932640"><institution-wrap><institution>National Heart, Lung, and Blood Institute</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000050</institution-id></institution-wrap></funding-source><award-id rid="funding1-1358863X20932640">K08HL131993</award-id></award-group><award-group id="award2-1358863X20932640"><funding-source id="funding2-1358863X20932640"><institution-wrap><institution>National Heart, Lung, and Blood Institute</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000050</institution-id></institution-wrap></funding-source><award-id rid="funding2-1358863X20932640">R01HL150392</award-id></award-group><award-group id="award3-1358863X20932640"><funding-source id="funding3-1358863X20932640"><institution-wrap><institution>Dr. Ralph and Marian Falk Medical Research
Trust</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100008590</institution-id></institution-wrap></funding-source><award-id rid="funding3-1358863X20932640">Catalyst Award</award-id></award-group><award-group id="award4-1358863X20932640"><funding-source id="funding4-1358863X20932640"><institution-wrap><institution>American Venous Forum</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100013442</institution-id></institution-wrap></funding-source><award-id rid="funding4-1358863X20932640">JOBST-AVFF award</award-id></award-group><award-group id="award5-1358863X20932640"><funding-source id="funding5-1358863X20932640"><institution-wrap><institution>Frankel Cardiovascular Center</institution><institution-id/></institution-wrap></funding-source><award-id rid="funding5-1358863X20932640">COVID-19 Cardiovascular Impact
Research Ignitor Gr</award-id></award-group><award-group id="award6-1358863X20932640"><funding-source id="funding6-1358863X20932640"><institution-wrap><institution>A. Alfred Taubman Medical Research Institute</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100008456</institution-id></institution-wrap></funding-source></award-group><award-group id="award7-1358863X20932640"><funding-source id="funding7-1358863X20932640"><institution-wrap><institution>University of Michigan Medical School</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100008455</institution-id></institution-wrap></funding-source><award-id rid="funding7-1358863X20932640">BioInterfaces Institute
Award</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-1358863X20932640"><title>Introduction</title><p>In December 2019, a new betacoronavirus (severe acute respiratory syndrome
coronavirus 2 [SARS-CoV-2]), thought to originate in Wuhan, China, emerged as a
novel human pathogen for viral pneumonia (coronavirus disease [COVID-19]), resulting
in an ongoing pandemic.<sup><xref rid="bibr1-1358863X20932640" ref-type="bibr">1</xref>,<xref rid="bibr2-1358863X20932640" ref-type="bibr">2</xref></sup>
The number of cases worldwide now exceeds five million, with more than 350,000
associated deaths, triggering a global effort to understand the predictors of
disease severity for rapid triage, and the pathology of disease for rational
therapeutic development and clinical trials. A consistent finding in early case
series in China and New York City is an association between elevations in D-dimer
and fibrin(ogen) degradation products (FDPs) and increasing COVID-19 severity and
mortality.<sup><xref rid="bibr3-1358863X20932640" ref-type="bibr">3</xref><xref rid="bibr4-1358863X20932640" ref-type="bibr"/><xref rid="bibr5-1358863X20932640" ref-type="bibr"/><xref rid="bibr6-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr7-1358863X20932640" ref-type="bibr">7</xref></sup> We aim to review the available
data on the coagulopathy observed in COVID-19 and draw from studies of prior viral
epidemics to explore possible mechanisms and therapies.</p><p>Coronaviruses are enveloped, non-segmented, positive-sense RNA viruses of the
<italic>Nidovirales</italic> order within the <italic>Coronaviridae</italic>
family. Different strains are infectious to a broad range of animals including
humans, bats, cats, racoon dogs, rabbits, pigs, and cattle.<sup><xref rid="bibr8-1358863X20932640" ref-type="bibr">8</xref></sup> In general,
coronavirus infections in humans are mild; however, two recent epidemics of
betacoronaviruses &#x02013; SARS in 2003<sup><xref rid="bibr9-1358863X20932640" ref-type="bibr">9</xref><xref rid="bibr10-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr11-1358863X20932640" ref-type="bibr">11</xref></sup> and Middle East Respiratory
Syndrome (MERS) in 2012<sup><xref rid="bibr12-1358863X20932640" ref-type="bibr">12</xref>,<xref rid="bibr13-1358863X20932640" ref-type="bibr">13</xref></sup> &#x02013; were associated with significant mortality with death rates
around 10% and 35%, respectively.<sup><xref rid="bibr14-1358863X20932640" ref-type="bibr">14</xref>,<xref rid="bibr15-1358863X20932640" ref-type="bibr">15</xref></sup> While the observed case
fatality rate for the COVID-19 pandemic is lower,<sup><xref rid="bibr16-1358863X20932640" ref-type="bibr">16</xref>,<xref rid="bibr17-1358863X20932640" ref-type="bibr">17</xref></sup> the population at risk is much
higher due to the global spread of the disease and the infectivity of the
virus,<sup><xref rid="bibr18-1358863X20932640" ref-type="bibr">18</xref></sup> and worldwide fatalities already exceed those in the prior
epidemics.</p><p>Common clinical manifestations of patients with COVID-19 include fever and cough, and
less commonly fatigue, dyspnea, headache, sore throat, anosmia, nausea, vomiting, or
diarrhea.<sup><xref rid="bibr6-1358863X20932640" ref-type="bibr">6</xref></sup> In the largest case series to date of over 44,000 patients with
COVID-19, &#x0003e; 75% of cases were mild, 14% were severe, and 5% were critical, with
an overall case fatality rate of 2&#x02013;2.5%. All deaths occurred in patients with
critical disease (in which the case fatality rate was almost 50%).<sup><xref rid="bibr19-1358863X20932640" ref-type="bibr">19</xref></sup> While the
majority of critically ill patients with COVID-19 have isolated respiratory failure,
often acute respiratory distress syndrome (ARDS), multiple organ dysfunction occurs
in 20&#x02013;30% of patients with critical illness and more often in fatal cases.<sup><xref rid="bibr16-1358863X20932640" ref-type="bibr">16</xref></sup> Hematologic
findings, such as mild to moderate thrombocytopenia and lymphopenia, are associated
with COVID-19;<sup><xref rid="bibr20-1358863X20932640" ref-type="bibr">20</xref>,<xref rid="bibr21-1358863X20932640" ref-type="bibr">21</xref></sup> however, the most significant and concerning vascular aspect of
this disease is coagulopathy. We have attempted to summarize the data on the
pathogenesis, epidemiology and outcomes related to COVID-19-coagulopathy and
thrombotic disease using PubMed as well as the pre-print server <ext-link ext-link-type="uri" xlink:href="https://medrxiv.org">https://medrxiv.org</ext-link> (date of last search April 23, 2020).</p></sec><sec id="section2-1358863X20932640"><title>Coagulopathy of SARS-CoV-2 and other infections</title><p>There is particular interest in the coagulopathy in patients with COVID-19 as
abnormal coagulation parameters, most consistently elevations in D-dimer and FDPs,
are associated with disease severity.<sup><xref rid="bibr22-1358863X20932640" ref-type="bibr">22</xref>,<xref rid="bibr23-1358863X20932640" ref-type="bibr">23</xref></sup> An elevated D-dimer, the most
common coagulation abnormality in COVID-19 (found in up to 45% of patients), is an
independent risk factor for death,<sup><xref rid="bibr6-1358863X20932640" ref-type="bibr">6</xref>,<xref rid="bibr22-1358863X20932640" ref-type="bibr">22</xref>,<xref rid="bibr24-1358863X20932640" ref-type="bibr">24</xref>,<xref rid="bibr25-1358863X20932640" ref-type="bibr">25</xref></sup> and patients with D-dimer
greater than 1000 ng/mL are almost 20 times more likely to die from their infection
than patients with lower D-dimer values.<sup><xref rid="bibr25-1358863X20932640" ref-type="bibr">25</xref></sup> In contrast, most patients
with COVID-19 have a normal or mildly prolonged prothrombin time (PT) and a normal
or shortened activated partial thromboplastin time (aPTT) on presentation and these
labs are not reliably associated with disease severity.<sup><xref rid="bibr5-1358863X20932640" ref-type="bibr">5</xref>,<xref rid="bibr17-1358863X20932640" ref-type="bibr">17</xref>,<xref rid="bibr22-1358863X20932640" ref-type="bibr">22</xref>,<xref rid="bibr24-1358863X20932640" ref-type="bibr">24</xref>,<xref rid="bibr25-1358863X20932640" ref-type="bibr">25</xref></sup> Both initial and longitudinal
monitoring of coagulation parameters can predict disease severity, as elevated
D-dimer and FDP levels on admission and decreased levels of fibrinogen and
antithrombin III during the admission are associated with death.<sup><xref rid="bibr23-1358863X20932640" ref-type="bibr">23</xref></sup> Although
changes in plasminogen activator inhibitor-1 (PAI-1) levels and activity have not
been studied, an increase in the PAI-1/tissue plasminogen activator (t-PA) ratio
would not be unexpected. These findings may be due to uncontrolled activation of
coagulation with ongoing consumption and widespread microvascular thrombosis.</p><p>While early descriptions of the coagulopathy identified it as disseminated
intravascular coagulation (DIC), in DIC, unlike in severe COVID-19, platelet count
and PT prolongation correlate with sepsis severity and mortality, while fibrinogen
and FDPs levels do not.<sup><xref rid="bibr26-1358863X20932640" ref-type="bibr">26</xref>,<xref rid="bibr27-1358863X20932640" ref-type="bibr">27</xref></sup> And while the majority of patients who die from COVID-19
develop some laboratory evidence of DIC during their admission, elevations in
D-dimer and prolonged PT with mild thrombocytopenia and normal fibrinogen are
commonly seen.<sup><xref rid="bibr23-1358863X20932640" ref-type="bibr">23</xref></sup> Thromboelastography in patients with COVID-19 in the ICU shows
a hypercoagulable state.<sup><xref rid="bibr28-1358863X20932640" ref-type="bibr">28</xref></sup> These observations suggest the underlying pathophysiology
in at least a subset of critically ill patients with COVID-19 is distinct from
traditional systemic DIC and may be due to a unique coagulopathy.</p><p>Elevations in D-dimer are common in critical illness and are associated with disease
severity and mortality in many severe infections.<sup><xref rid="bibr29-1358863X20932640" ref-type="bibr">29</xref><xref rid="bibr30-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr31-1358863X20932640" ref-type="bibr">31</xref></sup> Patients with influenza, SARS,
HIV, hantavirus, Ebola virus, and dengue have elevations in D-dimer, prothrombin
fragments, thrombin&#x02013;antithrombin complexes, and/or plasmin-&#x003b1;<sub>2</sub>-antiplasmin
complexes.<sup><xref rid="bibr32-1358863X20932640" ref-type="bibr">32</xref></sup> Similar to patients with SARS-CoV-2 infections, there is an
association between elevated D-dimer and mortality in patients with H1N1 and H5N1,
which is not seen in SARS.<sup><xref rid="bibr33-1358863X20932640" ref-type="bibr">33</xref><xref rid="bibr34-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr35-1358863X20932640" ref-type="bibr">35</xref></sup></p><p>Additionally, in the H1N1 pandemic, patients with severe disease had high rates of
venous thromboembolism (VTE) and many patients with thromboembolism did not have
evidence of systemic DIC.<sup><xref rid="bibr36-1358863X20932640" ref-type="bibr">36</xref><xref rid="bibr37-1358863X20932640" ref-type="bibr"/><xref rid="bibr38-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr39-1358863X20932640" ref-type="bibr">39</xref></sup> Patients with ARDS from H1N1
infection had a greater than 20-fold increase in risk of pulmonary embolism compared
to patients with ARDS unrelated to H1N1.<sup><xref rid="bibr39-1358863X20932640" ref-type="bibr">39</xref></sup> Empiric therapeutic
anticoagulation in patients with ARDS was associated with decreased rates of VTE in
patients with ARDS from H1N1, but had no effect on VTE rates in patients with ARDS
unrelated to H1N1 infection. There are reports of VTE in patients with COVID-19,
despite concerns regarding underdiagnosis given baseline elevations in D-dimer, as
well as pragmatic challenges in diagnostic imaging while in isolation, including use
of personal protective equipment and longer duration of exposure of health care
workers.<sup><xref rid="bibr40-1358863X20932640" ref-type="bibr">40</xref>,<xref rid="bibr41-1358863X20932640" ref-type="bibr">41</xref></sup> Although data remain scarce, there are increasing reports of
arterial thrombotic events including ischemic strokes in patients with
COVID-19.<sup><xref rid="bibr41-1358863X20932640" ref-type="bibr">41</xref><xref rid="bibr42-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr43-1358863X20932640" ref-type="bibr">43</xref></sup> Myocardial
injury, defined by elevations in cardiac troponin levels, is common in patients
hospitalized with COVID-19 and is associated with severe disease and high risk of
mortality.<sup><xref rid="bibr44-1358863X20932640" ref-type="bibr">44</xref>,<xref rid="bibr45-1358863X20932640" ref-type="bibr">45</xref></sup> Myocardial injury may result from systemic inflammatory
response syndrome (SIRS) and inflammation as well as due to acute thrombotic
events.<sup><xref rid="bibr46-1358863X20932640" ref-type="bibr">46</xref>,<xref rid="bibr47-1358863X20932640" ref-type="bibr">47</xref></sup> Similar observations of myocardial injury have been found in
patients with other viral infections.<sup><xref rid="bibr48-1358863X20932640" ref-type="bibr">48</xref>,<xref rid="bibr49-1358863X20932640" ref-type="bibr">49</xref></sup></p></sec><sec id="section3-1358863X20932640"><title>Pathologic findings in SARS-CoV-2 infection</title><p>Although there are only a few published pathologic reports of patients with COVID-19,
histopathology of lung specimens from patients with early disease shows
characteristic findings of ARDS and evidence of small vessel occlusion.<sup><xref rid="bibr50-1358863X20932640" ref-type="bibr">50</xref>,<xref rid="bibr51-1358863X20932640" ref-type="bibr">51</xref></sup> There are
several mechanisms by which SARS-CoV-2 infection may result in microvascular and
macrovascular thrombosis, including cytokine storm with activation of leukocytes,
endothelium and platelets resulting in upregulation of tissue factor, activation of
coagulation, thrombin generation and fibrin formation,<sup><xref rid="bibr52-1358863X20932640" ref-type="bibr">52</xref></sup> deranged coagulation with
imbalances in PAI-1, tissue factor pathway inhibitor, and activated protein C that
promotes fibrin generation and limits fibrinolysis,<sup><xref rid="bibr53-1358863X20932640" ref-type="bibr">53</xref>,<xref rid="bibr54-1358863X20932640" ref-type="bibr">54</xref></sup> hypoxic vaso-occlusion, and
direct viral effects with cell activation (<xref ref-type="fig" rid="fig1-1358863X20932640">Figure 1</xref>). It remains an active area of
investigation whether these are specific to SARS-CoV-2 infection or a final common
pathway in the thromboinflammatory response to viral infections and a marker of
disease severity. Early COVID-19 autopsy reports have also identified a possible
role for neutrophils as microvascular thrombi contained numerous neutrophils, which
in some cases were partially degenerated, consistent with neutrophil extracellular
traps (NETs).<sup><xref rid="bibr55-1358863X20932640" ref-type="bibr">55</xref>,<xref rid="bibr56-1358863X20932640" ref-type="bibr">56</xref></sup> NETs are tangles of DNA released from neutrophils, and are
decorated with antimicrobial and nuclear proteins that propagate intravascular
thrombosis.<sup><xref rid="bibr57-1358863X20932640" ref-type="bibr">57</xref>,<xref rid="bibr58-1358863X20932640" ref-type="bibr">58</xref></sup> NETs initiate both the extrinsic and contact pathways by
augmenting presentation of tissue factor, activation of factor XII (FXII), as well
as trapping and activating platelets.<sup><xref rid="bibr59-1358863X20932640" ref-type="bibr">59</xref><xref rid="bibr60-1358863X20932640" ref-type="bibr"/><xref rid="bibr61-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr62-1358863X20932640" ref-type="bibr">62</xref></sup> Consistent with these
observations, patients with severe COVID-19 have elevated serum markers of
neutrophil activation and NET formation.<sup><xref rid="bibr63-1358863X20932640" ref-type="bibr">63</xref></sup> In one study, neutrophil
activation measured in serum correlated with, and sometimes preceded, VTE in
patients with COVID-19.<sup><xref rid="bibr64-1358863X20932640" ref-type="bibr">64</xref></sup></p><fig id="fig1-1358863X20932640" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Immune activation and mechanisms of coagulopathy in patients with coronavirus
disease 2019 (COVID-19).</p><p>Multiple processes may contribute to COVID-19-associated coagulopathy
including direct infection of type II pneumocytes and endothelial cells,
leading to barrier dysfunction and increased permeability; inflammatory
responses characterized by activation of T cells, neutrophils, monocytes,
macrophages, and platelets resulting in exuberant inflammatory cytokine
release (including IL-1, IL-6, IL-10, TNF-&#x003b1;), monocyte-derived TF and PAI-1
expression; and culminating in the development of microvascular and
macrovascular thrombi composed of fibrin, NETs, and platelets.</p><p>IL, interleukin; NETs, neutrophil extracellular traps; PAI-1, plasminogen
activator inhibitor-1; TF, tissue factor; TNF-&#x003b1;, tumor necrosis
factor-alpha.</p></caption><graphic xlink:href="10.1177_1358863X20932640-fig1"/></fig></sec><sec id="section4-1358863X20932640"><title>Dysregulation of hemostasis and coagulopathy in acute respiratory distress
syndrome (ARDS)</title><p>Thrombi in the pulmonary micro- and macrovasculature are observed in patients with
ARDS with or without overt DIC, and changes consistent with a prothrombotic state
have been found both in blood and in alveolar fluid studies of these
patients.<sup><xref rid="bibr65-1358863X20932640" ref-type="bibr">65</xref>,<xref rid="bibr66-1358863X20932640" ref-type="bibr">66</xref></sup> Higher levels of FDPs and D-dimer are seen in patients who
developed ARDS as compared to patients with similar predisposing conditions that did
not develop ARDS.<sup><xref rid="bibr67-1358863X20932640" ref-type="bibr">67</xref></sup> Lower levels of protein C and higher levels of soluble
thrombomodulin and PAI-1 are also associated with multiple organ failure, disease
severity, and mortality in ARDS in some studies.<sup><xref rid="bibr53-1358863X20932640" ref-type="bibr">53</xref>,<xref rid="bibr68-1358863X20932640" ref-type="bibr">68</xref><xref rid="bibr69-1358863X20932640" ref-type="bibr"/><xref rid="bibr70-1358863X20932640" ref-type="bibr"/><xref rid="bibr71-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr72-1358863X20932640" ref-type="bibr">72</xref></sup> Finally, plasma and alveolar
levels of tissue factor are higher in patients with ARDS than patients with
pulmonary edema.<sup><xref rid="bibr73-1358863X20932640" ref-type="bibr">73</xref></sup> Mechanistically, there is increased thrombin generation by
tissue factor coupled with an impaired fibrinolytic response due to elevations in
PAI-1. Elevations in D-dimer, a breakdown product of crosslinked fibrin, may result
from residual t-PA/plasmin activity, as well as from alternative fibrinolytic
pathways such as human neutrophil elastase activity.<sup><xref rid="bibr74-1358863X20932640" ref-type="bibr">74</xref>,<xref rid="bibr75-1358863X20932640" ref-type="bibr">75</xref></sup></p><p>As patients with COVID-19 frequently have isolated pulmonary findings, the initial
hemostatic dysregulation may be localized to the lungs as a consequence of the
bidirectional relationship between the innate immune system and thrombosis.
Activated platelets through degranulation and coordinated interactions with
monocytes, dendritic cells, and neutrophils, as well as activated T cells, NETs,
tissue factor-bearing microparticles, and coagulation proteases may facilitate this
crosstalk.<sup><xref rid="bibr54-1358863X20932640" ref-type="bibr">54</xref>,<xref rid="bibr76-1358863X20932640" ref-type="bibr">76</xref>,<xref rid="bibr77-1358863X20932640" ref-type="bibr">77</xref></sup> In this model, immune cells, inflammatory cytokines, and
pathogen-associated molecular patterns induce thrombi consisting of fibrin,
monocytes, neutrophils, and platelets.<sup><xref rid="bibr57-1358863X20932640" ref-type="bibr">57</xref>,<xref rid="bibr58-1358863X20932640" ref-type="bibr">58</xref>,<xref rid="bibr78-1358863X20932640" ref-type="bibr">78</xref></sup> These immunothrombi initially
serve a protective purpose, promoting pathogen recognition and creating a sterile
barrier against further pathogen invasion, but can become maladaptive and injurious
to tissue and organ perfusion.<sup><xref rid="bibr57-1358863X20932640" ref-type="bibr">57</xref>,<xref rid="bibr79-1358863X20932640" ref-type="bibr">79</xref>,<xref rid="bibr80-1358863X20932640" ref-type="bibr">80</xref></sup> During this process, there is
abundant intra- and extra-vascular fibrin deposition and impaired fibrinolysis,
which has been well described in ARDS.<sup><xref rid="bibr81-1358863X20932640" ref-type="bibr">81</xref>,<xref rid="bibr82-1358863X20932640" ref-type="bibr">82</xref></sup> In postmortem studies, both
macro- and microvascular thrombi are common in patients in ARDS (observed in up to
95% of patients).<sup><xref rid="bibr82-1358863X20932640" ref-type="bibr">82</xref>,<xref rid="bibr83-1358863X20932640" ref-type="bibr">83</xref></sup> In COVID-19, the alveolar immunothrombotic response may be an
attempt to limit dissemination of SARS-CoV-2 outside the alveoli.</p><p>Findings from the SARS epidemic provide possible viral-specific mechanisms for ARDS
and uncontrolled coagulation. Autopsy studies of patients who died of SARS
pneumonia, identified the SARS-CoV spike (S) protein in cells expressing the
receptor angiotensin-converting enzyme 2 (ACE2),<sup><xref rid="bibr84-1358863X20932640" ref-type="bibr">84</xref><xref rid="bibr85-1358863X20932640" ref-type="bibr"/><xref rid="bibr86-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr87-1358863X20932640" ref-type="bibr">87</xref></sup> the leading candidate receptor
for SARS-CoV-2.<sup><xref rid="bibr88-1358863X20932640" ref-type="bibr">88</xref>,<xref rid="bibr89-1358863X20932640" ref-type="bibr">89</xref></sup> Binding of the S protein to ACE2 induces expression of a
nuclear factor kappa B (NF&#x003ba;B)-driven inflammatory module, resulting in production of
proinflammatory cytokines including monocyte chemoattractant protein 1 (MCP-1),
transforming growth factor-beta 1 (TGF-&#x003b2;1), tumor necrosis factor-alpha (TNF-&#x003b1;),
interleukin (IL)-1&#x003b2;, and IL-6, which have been implicated in
thrombogenesis.<sup><xref rid="bibr90-1358863X20932640" ref-type="bibr">90</xref></sup> Although inflammatory responses are important in
host-defense, hyperinflammatory responses result in tissue damage, disruption of the
endothelial barrier, and uncontrolled activation of coagulation.<sup><xref rid="bibr54-1358863X20932640" ref-type="bibr">54</xref></sup> Overall, these
findings are consistent with a model in which SARS-CoV and SARS-CoV-2 directly
infect endothelial and epithelial cells, increasing levels of proinflammatory
cytokines, causing immune-mediated damage to the vasculature and surrounding tissue,
with exposure of tissue factor and associated thromboinflammatory changes.<sup><xref rid="bibr91-1358863X20932640" ref-type="bibr">91</xref></sup> While these
changes appear to be predominantly in the lungs, endotheliitis in COVID-19 has been
observed in kidneys, liver, heart, and intestine.<sup><xref rid="bibr91-1358863X20932640" ref-type="bibr">91</xref></sup></p><p>Additional studies in SARS-CoV and influenza found dysregulation of urokinase,
coagulation, and fibrinolysis pathways contributed to the severity of lung injury,
possibly through altering the hemostatic balance with subsequent coagulation-induced
ischemic injury.<sup><xref rid="bibr92-1358863X20932640" ref-type="bibr">92</xref></sup> Plasminogen was protective against severe influenza A, H5N1,
and H1N1 infections.<sup><xref rid="bibr93-1358863X20932640" ref-type="bibr">93</xref></sup> These groups hypothesized that increased fibrinolysis led
to a positive feedback loop of vascular permeability, leukocyte recruitment, and
fibrin generation. Interestingly, one hypothesis suggests that elevated plasminogen
may be a risk factor for SARS-CoV-2 infection because plasmin may cleave the S
protein of the virus and increase its infectivity.<sup><xref rid="bibr94-1358863X20932640" ref-type="bibr">94</xref></sup> These findings highlight the
delicate balance between corralling infection and uncontrolled inflammation and
thrombosis.</p></sec><sec id="section5-1358863X20932640"><title>Therapeutic considerations</title><p>Markers of hypercoagulability and higher inflammatory mediators are consistently
associated with worse outcomes in patients with ARDS and sepsis. These observations
have led to numerous clinical trials targeting various components of inflammatory
and coagulation pathways in acute lung injury, ARDS or sepsis. Studies with heparin,
steroids, non-steroidal anti-inflammatory drugs, and TNF-&#x003b1; inhibitors have been
disappointing.<sup><xref rid="bibr95-1358863X20932640" ref-type="bibr">95</xref><xref rid="bibr96-1358863X20932640" ref-type="bibr"/><xref rid="bibr97-1358863X20932640" ref-type="bibr"/><xref rid="bibr98-1358863X20932640" ref-type="bibr"/><xref rid="bibr99-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr100-1358863X20932640" ref-type="bibr">100</xref></sup></p><p>Given the laboratory and clinical findings in patients with severe COVID-19, several
repurposed and novel therapies are under investigation in clinical trials to prevent
the hyperinflammatory response or mitigate uncontrolled coagulation. As elevations
in D-dimer and FDPs likely reflect ongoing lung injury and microvascular thrombi,
possible therapeutic targets include inflammatory cytokines, activated platelets,
neutrophils, or microparticles that may propagate thrombosis; or anticoagulants and
fibrinolytics that could limit thrombosis. Supporting this enthusiasm was a recent
retrospective study in China in which VTE prophylaxic dose heparin was associated
with a survival benefit in patients with severe COVID-19 and evidence of
sepsis-induced coagulopathy.<sup><xref rid="bibr101-1358863X20932640" ref-type="bibr">101</xref></sup> The study found no benefit
among patients with milder COVID-19 illness; however, the study did not control for
other markers of disease severity nor other therapies, such as antivirals. The study
raises the possibility that prophylactic or therapeutic anticoagulation may benefit
patients with severe infection. Heparin may alter the biology of the disease not
only through its anticoagulant properties, but also due to its anti-inflammatory
effects that promote a quiescent endothelium.</p><p>Current expert recommendations, including interim guidelines from the International
Society on Thrombosis and Haemostasis (ISTH) and the American College of Cardiology
(ACC), recommend use of prophylactic dose LMWH or unfractionated heparin in all
COVID-19 patients requiring hospital admission; for patients with a contraindication
to pharmacologic prophylaxis, mechanical prophylaxis should be used.<sup><xref rid="bibr102-1358863X20932640" ref-type="bibr">102</xref>,<xref rid="bibr103-1358863X20932640" ref-type="bibr">103</xref></sup> While a
number of VTE risk stratification tools exist for hospitalized medical patients,
these have not been validated in patients with COVID-19. Extended VTE prophylaxis
with LMWH or direct oral anticoagulants after hospitalization for acute medical
illness reduces the risk of VTE with an associated increased risk of
bleeding.<sup><xref rid="bibr104-1358863X20932640" ref-type="bibr">104</xref><xref rid="bibr105-1358863X20932640" ref-type="bibr"/>&#x02013;<xref rid="bibr106-1358863X20932640" ref-type="bibr">106</xref></sup> There are
currently no data regarding extended prophylaxis in patients with COVID-19; however,
the ACC expert opinion statement recommends consideration of extended prophylaxis in
patients with elevated risk of VTE, such as patients with cancer or prolonged
immobility who have low bleeding risk. Given early reports and ongoing concerns of
high rates of VTE, randomized trials of empiric therapeutic anticoagulation or
antifibrinolytics are ongoing, and there are reports of empiric therapeutic
anticoagulation in patients with significantly elevated D-dimer both in Italy and in
the US. While heparin offers both anti-inflammatory and anticoagulant effects, the
benefit of therapeutic anticoagulation remains uncertain, with a risk of bleeding
complications in critically ill patients with respiratory failure.<sup><xref rid="bibr95-1358863X20932640" ref-type="bibr">95</xref>,<xref rid="bibr107-1358863X20932640" ref-type="bibr">107</xref></sup> Clinical
trials will help define the role of heparin in the treatment of hospitalized
patients with COVID-19. Outside of a trial setting, we advocate universal
standard-dose pharmacologic VTE prophylaxis in patients without a contraindication.
In patients with a high suspicion of VTE where access to confirmatory or serial
imaging is limited, clinicians may consider empiric anticoagulation, although there
is a paucity of evidence to provide guidance in this context. There are currently no
randomized data to recommend empiric therapeutic or intermediate-dose
anticoagulation in patients without documented VTE, or an other indication for
anticoagulation, or outside the context of a clinical trial. A recent retrospective,
observational study in New York City showed therapeutic anticoagulation was
associated with decreased mortality in patients with COVID-19 who required
mechanical ventilation, but not in all hospitalized patients with COVID-19. Although
these findings are provocative, interpretation is limited by their observational
nature.<sup><xref rid="bibr108-1358863X20932640" ref-type="bibr">108</xref></sup></p><p>There are over 300 trials ongoing for patients with COVID-19, many of which aim to
simultaneously reduce inflammation and thrombosis, including cytokine-directed
therapies (against IL-1, IL-6, interferon gamma), corticosteroids, Janus kinase
inhibitors, TLR ligands, complement inhibitors, <italic>N</italic>-acetylcysteine,
serine protease inhibitors, DNAse enzymes, and anti-viral agents. However,
suppressing the cytokine storm or hypercoagulability may be insufficient once
initiated, and targeting upstream pathways to prevent activation of this
self-amplifying feedback loop may be more effective.</p><p>One therapeutic candidate to treat COVID-19 is dipyridamole, an adenosinergic drug
indicated for use as an arterial thromboembolic prophylaxis agent in combination
with aspirin or warfarin.<sup><xref rid="bibr109-1358863X20932640" ref-type="bibr">109</xref></sup> Dipyridamole has recently been shown to suppress human
neutrophil and T-cell activation, upstream of cytokine effectors.<sup><xref rid="bibr58-1358863X20932640" ref-type="bibr">58</xref>,<xref rid="bibr110-1358863X20932640" ref-type="bibr">110</xref></sup> Dipyridamole
induces a type I interferon response, which is necessary for physiologic anti-viral
activity, and inhibits SARS-CoV-2 replication <italic>in vitro</italic> by
inhibiting a critical viral replication complex.<sup><xref rid="bibr111-1358863X20932640" ref-type="bibr">111</xref>,<xref rid="bibr112-1358863X20932640" ref-type="bibr">112</xref></sup> Administered orally,
dipyridamole has a favorable safety profile, and a small clinical trial in patients
with COVID-19 suggests it may improve D-dimer levels.<sup><xref rid="bibr113-1358863X20932640" ref-type="bibr">113</xref></sup> Randomized clinical trials
of agents active at the intersection of inflammation and coagulation in COVID-19,
such as dipyridamole, t-PA, and heparin are necessary to determine if these
therapeutics can restore the balance of inflammation and coagulation without
dampening early or late physiologic anti-viral responses. The heterogenous response
to the SARS-CoV-2 infection and the various time-dependent pathways driving
pathology make universal therapies challenging. The temporal and mechanistic role
each pathway plays in severe SARS-CoV-2 infection remains uncertain and requires
further exploration for treatment opportunities as efforts to control this pandemic
continue.</p></sec><sec sec-type="conclusions" id="section6-1358863X20932640"><title>Conclusions</title><p>In conclusion, in patients with COVID-19, the presence of coagulopathy, characterized
by elevations in D-dimer and FDPs, is consistently associated with more severe
illness and mortality. Laboratory, clinical, and early histopathologic findings
suggest this coagulopathy is distinct from sepsis-induced DIC and may reflect
dysregulated hemostasis. Similar findings have been associated with several other
viral infections, and it remains uncertain if this coagulopathy is specific to
SARS-CoV-2 or the end common pathway of the thrombo-inflammatory response to severe
viral infections. There are efforts to target numerous components of the
thrombo-inflammatory pathway to improve outcomes in patients with severe COVID-19.
The optimal management for these patients including strategies to diagnose VTE,
appropriate anticoagulation doses and duration, and effectiveness of novel therapies
are under active investigation in the current pandemic.</p></sec></body><back><ack><p>The authors would like to thank Charles Bolan, MD and Jason Knight, MD, PhD for
guidance and review of the manuscript, and all members of the &#x02018;NETwork to Target
Neutrophils in COVID-19&#x02019; and the SVM Next Generation Committee for their helpful
advice and encouragement. The authors credit Alan Hoofring for the illustration.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Declaration of conflicting interests:</bold> The authors declared the following potential conflicts of interest with respect
to the research, authorship, and/or publication of this article: YK has served
as a consultant for Surface Oncology and has a pending patent on use of biogases
in vascular disease. Neither author has related financial conflicts of interest
to disclose.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: MEC is supported by
the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes
of Health (NIH). YK is supported by grant funding from the NIH-NHLBI
(K08HL131993, R01HL150392), A. Alfred Taubman Medical Research Institute,
Michigan Medicine Frankel COVID-19 Cardiovascular Impact Research Ignitor
Program, Falk Medical Research Trust Catalyst Award, American Venous Forum-JOBST
Award, University of Michigan BioInterfaces Institute, and Bo Schembechler Heart
of A Champion Foundation.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Yogendra Kanthi <inline-graphic xlink:href="10.1177_1358863X20932640-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-5660-5194">https://orcid.org/0000-0002-5660-5194</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1358863X20932640"><label>1</label><mixed-citation publication-type="web">
<collab>World Health Organization</collab>. <article-title>Pneumonia of unknown
cause &#x02013; China</article-title>. <source>Disease outbreak news</source>,
<day>5</day>
<month>1</month>, <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/">https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/</ext-link>
(2020, accessed <day>25</day>
<month>3</month>
<year>2020</year>).</mixed-citation></ref><ref id="bibr2-1358863X20932640"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>
<article-title>A novel coronavirus from
patients with pneumonia in China, 2019</article-title>. <source>N Engl J
Med</source>
<year>2020</year>; <volume>382</volume>:
<fpage>727</fpage>&#x02013;<lpage>733</lpage>.<pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation></ref><ref id="bibr3-1358863X20932640"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Diagnostic utility of
clinical laboratory data determinations for patients with the severe
COVID-19</article-title>. <source>J Med Virol</source>. Epub ahead of print
17 Mar 2020. DOI: <pub-id pub-id-type="doi">10.1002/jmv.25770</pub-id>.</mixed-citation></ref><ref id="bibr4-1358863X20932640"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wan</surname><given-names>S</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>
<article-title>Clinical features and
treatment of COVID-19 patients in northeast Chongqing</article-title>.
<source>J Med Virol</source>. Epub ahead of print 21 Mar 2020. DOI: <pub-id pub-id-type="doi">10.1002/jmv.25783</pub-id>.</mixed-citation></ref><ref id="bibr5-1358863X20932640"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Clinical features of
patients infected with 2019 novel coronavirus in Wuhan,
China</article-title>. <source>Lancet</source>
<year>2020</year>; <volume>395</volume>:
<fpage>497</fpage>&#x02013;<lpage>506</lpage>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="bibr6-1358863X20932640"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><name><surname>Ni</surname><given-names>ZY</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Clinical characteristics of
coronavirus disease 2019 in China</article-title>. <source>N Engl J
Med</source>
<year>2020</year>; <volume>382</volume>:
<fpage>1708</fpage>&#x02013;<lpage>1720</lpage>.<pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref><ref id="bibr7-1358863X20932640"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petrilli</surname><given-names>CM</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Factors associated with
hospitalization and critical illness among 4,103 patients with COVID-19
disease in New York City</article-title>. <source>BMJ</source>
<year>2020</year>; <volume>369</volume>: <fpage>m1966</fpage>.<pub-id pub-id-type="pmid">32444366</pub-id></mixed-citation></ref><ref id="bibr8-1358863X20932640"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saif</surname><given-names>LJ.</given-names></name></person-group>
<article-title>Animal coronavirus vaccines: lessons for SARS</article-title>.
<source>Dev Biol (Basel)</source>
<year>2004</year>; <volume>119</volume>:
<fpage>129</fpage>&#x02013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">15742624</pub-id></mixed-citation></ref><ref id="bibr9-1358863X20932640"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuiken</surname><given-names>T</given-names></name><name><surname>Fouchier</surname><given-names>RA</given-names></name><name><surname>Schutten</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Newly discovered coronavirus
as the primary cause of severe acute respiratory syndrome</article-title>.
<source>Lancet</source>
<year>2003</year>; <volume>362</volume>:
<fpage>263</fpage>&#x02013;<lpage>270</lpage>.<pub-id pub-id-type="pmid">12892955</pub-id></mixed-citation></ref><ref id="bibr10-1358863X20932640"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Gunther</surname><given-names>S</given-names></name><name><surname>Preiser</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>
<article-title>Identification of a novel
coronavirus in patients with severe acute respiratory
syndrome</article-title>. <source>N Engl J Med</source>
<year>2003</year>; <volume>348</volume>:
<fpage>1967</fpage>&#x02013;<lpage>1976</lpage>.<pub-id pub-id-type="pmid">12690091</pub-id></mixed-citation></ref><ref id="bibr11-1358863X20932640"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ksiazek</surname><given-names>TG</given-names></name><name><surname>Erdman</surname><given-names>D</given-names></name><name><surname>Goldsmith</surname><given-names>CS</given-names></name></person-group>, <etal>et al</etal>
<article-title>A novel coronavirus
associated with severe acute respiratory syndrome</article-title>. <source>N
Engl J Med</source>
<year>2003</year>; <volume>348</volume>:
<fpage>1953</fpage>&#x02013;<lpage>1966</lpage>.<pub-id pub-id-type="pmid">12690092</pub-id></mixed-citation></ref><ref id="bibr12-1358863X20932640"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Groot</surname><given-names>RJ</given-names></name><name><surname>Baker</surname><given-names>SC</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Middle East respiratory
syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study
Group</article-title>. <source>J Virol</source>
<year>2013</year>; <volume>87</volume>:
<fpage>7790</fpage>&#x02013;<lpage>7792</lpage>.<pub-id pub-id-type="pmid">23678167</pub-id></mixed-citation></ref><ref id="bibr13-1358863X20932640"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zaki</surname><given-names>AM</given-names></name><name><surname>van Boheemen</surname><given-names>S</given-names></name><name><surname>Bestebroer</surname><given-names>TM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Isolation of a novel
coronavirus from a man with pneumonia in Saudi Arabia</article-title>.
<source>N Engl J Med</source>
<year>2012</year>; <volume>367</volume>:
<fpage>1814</fpage>&#x02013;<lpage>1820</lpage>.<pub-id pub-id-type="pmid">23075143</pub-id></mixed-citation></ref><ref id="bibr14-1358863X20932640"><label>14</label><mixed-citation publication-type="web">
<collab>World Health Organization</collab>. <article-title>Summary of probable
SARS cases with onset of illness from 1 November 2002 to 31 July
2003</article-title>, <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/country/table2004_04_21/en/">https://www.who.int/csr/sars/country/table2004_04_21/en/</ext-link>
(<year>2003</year>, accessed 28 March 2020).</mixed-citation></ref><ref id="bibr15-1358863X20932640"><label>15</label><mixed-citation publication-type="web">
<collab>World Health Organization</collab>. <article-title>Middle East
respiratory syndrome coronavirus (MERS-CoV)</article-title>. <source>MERS
Monthly Summary</source>, <month>11</month>
<year>2019</year>, <ext-link ext-link-type="uri" xlink:href="http://www.who.int/emergencies/mers-cov/en/">http://www.who.int/emergencies/mers-cov/en/</ext-link> (<year>2019</year>,
<comment>accessed 27 March 2020</comment>).</mixed-citation></ref><ref id="bibr16-1358863X20932640"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Clinical course and outcomes
of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A
single-centered, retrospective, observational study</article-title>.
<source>Lancet Respir Med</source>
<year>2020</year>; <volume>8</volume>:
<fpage>475</fpage>&#x02013;<lpage>481</lpage>.<pub-id pub-id-type="pmid">32105632</pub-id></mixed-citation></ref><ref id="bibr17-1358863X20932640"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Clinical characteristics of
138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in
Wuhan, China</article-title>. <source>JAMA</source>
<year>2020</year>; <volume>323</volume>:
<fpage>1061</fpage>&#x02013;<lpage>1069</lpage>.</mixed-citation></ref><ref id="bibr18-1358863X20932640"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petrosillo</surname><given-names>N</given-names></name><name><surname>Viceconte</surname><given-names>G</given-names></name><name><surname>Ergonul</surname><given-names>O</given-names></name></person-group>, <etal>et al</etal>
<article-title>COVID-19, SARS and MERS: Are
they closely related?</article-title>
<source>Clin Microbiol Infect</source>
<year>2020</year>;
<volume>26</volume>:<fpage>729</fpage>&#x02013;<lpage>734</lpage>.<pub-id pub-id-type="pmid">32234451</pub-id></mixed-citation></ref><ref id="bibr19-1358863X20932640"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>McGoogan</surname><given-names>JM.</given-names></name></person-group>
<article-title>Characteristics of and important lessons from the coronavirus
disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314
cases from the Chinese Center for Disease Control and
Prevention</article-title>. <source>JAMA</source>
<year>2020</year>; <volume>323</volume>:
<fpage>1239</fpage>&#x02013;<lpage>1242</lpage>.</mixed-citation></ref><ref id="bibr20-1358863X20932640"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name></person-group>, <etal>et al</etal>
<article-title>A pneumonia outbreak
associated with a new coronavirus of probable bat origin</article-title>.
<source>Nature</source>
<year>2020</year>; <volume>579</volume>:
<fpage>270</fpage>&#x02013;<lpage>273</lpage>.<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="bibr21-1358863X20932640"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G</given-names></name><name><surname>Plebani</surname><given-names>M</given-names></name><name><surname>Henry</surname><given-names>BM.</given-names></name></person-group>
<article-title>Thrombocytopenia is associated with severe coronavirus disease
2019 (COVID-19) infections: A meta-analysis</article-title>. <source>Clin
Chim Acta</source>
<year>2020</year>; <volume>506</volume>:
<fpage>145</fpage>&#x02013;<lpage>148</lpage>.<pub-id pub-id-type="pmid">32178975</pub-id></mixed-citation></ref><ref id="bibr22-1358863X20932640"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Risk factors associated with
acute respiratory distress syndrome and death in patients with coronavirus
disease 2019 pneumonia in Wuhan, China</article-title>. <source>JAMA Intern
Med</source>. Epub ahead of print 13 Mar 2020. DOI: <pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id>.</mixed-citation></ref><ref id="bibr23-1358863X20932640"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Abnormal coagulation
parameters are associated with poor prognosis in patients with novel
coronavirus pneumonia</article-title>. <source>J Thromb Haemost</source>
<year>2020</year>; <volume>18</volume>:
<fpage>844</fpage>&#x02013;<lpage>847</lpage>.<pub-id pub-id-type="pmid">32073213</pub-id></mixed-citation></ref><ref id="bibr24-1358863X20932640"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,
China: A descriptive study</article-title>. <source>Lancet</source>
<year>2020</year>; <volume>395</volume>:
<fpage>507</fpage>&#x02013;<lpage>513</lpage>.<pub-id pub-id-type="pmid">32007143</pub-id></mixed-citation></ref><ref id="bibr25-1358863X20932640"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Clinical course and risk
factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A
retrospective cohort study</article-title>. <source>Lancet</source>
<year>2020</year>; <volume>395</volume>:
<fpage>1054</fpage>&#x02013;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="bibr26-1358863X20932640"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iba</surname><given-names>T</given-names></name><name><surname>Levy</surname><given-names>JH</given-names></name><name><surname>Warkentin</surname><given-names>TE</given-names></name></person-group>, <etal>et al</etal>
<article-title>Diagnosis and management of
sepsis-induced coagulopathy and disseminated intravascular
coagulation</article-title>. <source>J Thromb Haemost</source>
<year>2019</year>; <volume>17</volume>:
<fpage>1989</fpage>&#x02013;<lpage>1994</lpage>.<pub-id pub-id-type="pmid">31410983</pub-id></mixed-citation></ref><ref id="bibr27-1358863X20932640"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iba</surname><given-names>T</given-names></name><name><surname>Di Nisio</surname><given-names>M</given-names></name><name><surname>Thachil</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>A proposal of the
modification of Japanese Society on Thrombosis and Hemostasis (JSTH)
Disseminated Intravascular Coagulation (DIC) diagnostic criteria for
sepsis-associated DIC</article-title>. <source>Clin Appl Thromb
Hemost</source>
<year>2018</year>; <volume>24</volume>:
<fpage>439</fpage>&#x02013;<lpage>445</lpage>.<pub-id pub-id-type="pmid">28747069</pub-id></mixed-citation></ref><ref id="bibr28-1358863X20932640"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Panigada</surname><given-names>M</given-names></name><name><surname>Bottino</surname><given-names>N</given-names></name><name><surname>Tagliabue</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>
<article-title>Hypercoagulability of
COVID-19 patients in intensive care unit. A report of thromboelastography
findings and other parameters of hemostasis</article-title>. <source>J
Thromb Haemost</source>. Epub ahead of print 17 April 2020. DOI: <pub-id pub-id-type="doi">10.1111/jth.14850</pub-id>.</mixed-citation></ref><ref id="bibr29-1358863X20932640"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shorr</surname><given-names>AF</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name><name><surname>Alkins</surname><given-names>SA</given-names></name></person-group>, <etal>et al</etal>
<article-title>D-dimer correlates with
proinflammatory cytokine levels and outcomes in critically ill
patients</article-title>. <source>Chest</source>
<year>2002</year>; <volume>121</volume>:
<fpage>1262</fpage>&#x02013;<lpage>1268</lpage>.<pub-id pub-id-type="pmid">11948062</pub-id></mixed-citation></ref><ref id="bibr30-1358863X20932640"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rodelo</surname><given-names>JR</given-names></name><name><surname>De la Rosa</surname><given-names>G</given-names></name><name><surname>Valencia</surname><given-names>ML</given-names></name></person-group>, <etal>et al</etal>
<article-title>D-dimer is a significant
prognostic factor in patients with suspected infection and
sepsis</article-title>. <source>Am J Emerg Med</source>
<year>2012</year>; <volume>30</volume>:
<fpage>1991</fpage>&#x02013;<lpage>1999</lpage>.<pub-id pub-id-type="pmid">22795996</pub-id></mixed-citation></ref><ref id="bibr31-1358863X20932640"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>
<article-title>Serum D-dimer levels at
admission for prediction of outcomes in acute pancreatitis</article-title>.
<source>BMC Gastroenterol</source>
<year>2019</year>; <volume>19</volume>: <fpage>67</fpage>.<pub-id pub-id-type="pmid">31046705</pub-id></mixed-citation></ref><ref id="bibr32-1358863X20932640"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goeijenbier</surname><given-names>M</given-names></name><name><surname>van Wissen</surname><given-names>M</given-names></name><name><surname>van de Weg</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Review: Viral infections and
mechanisms of thrombosis and bleeding</article-title>. <source>J Med
Virol</source>
<year>2012</year>; <volume>84</volume>:
<fpage>1680</fpage>&#x02013;<lpage>1696</lpage>.<pub-id pub-id-type="pmid">22930518</pub-id></mixed-citation></ref><ref id="bibr33-1358863X20932640"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>RS</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>To</surname><given-names>KF</given-names></name></person-group>, <etal>et al</etal>
<article-title>Haematological
manifestations in patients with severe acute respiratory syndrome:
Retrospective analysis</article-title>. <source>BMJ</source>
<year>2003</year>; <volume>326</volume>:
<fpage>1358</fpage>&#x02013;<lpage>1362</lpage>.<pub-id pub-id-type="pmid">12816821</pub-id></mixed-citation></ref><ref id="bibr34-1358863X20932640"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soepandi</surname><given-names>PZ</given-names></name><name><surname>Burhan</surname><given-names>E</given-names></name><name><surname>Mangunnegoro</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Clinical course of avian
influenza A(H5N1) in patients at the Persahabatan Hospital, Jakarta,
Indonesia, 2005&#x02013;2008</article-title>. <source>Chest</source>
<year>2010</year>; <volume>138</volume>:
<fpage>665</fpage>&#x02013;<lpage>673</lpage>.<pub-id pub-id-type="pmid">20507944</pub-id></mixed-citation></ref><ref id="bibr35-1358863X20932640"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZF</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>XJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Serum D-dimer changes and
prognostic implication in 2009 novel influenza A(H1N1)</article-title>.
<source>Thromb Res</source>
<year>2011</year>; <volume>127</volume>:
<fpage>198</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">21216444</pub-id></mixed-citation></ref><ref id="bibr36-1358863X20932640"><label>36</label><mixed-citation publication-type="journal">
<collab>Centers for Disease Control and Prevention</collab>.
<article-title>Intensive-care patients with severe novel influenza A (H1N1)
virus infection &#x02013; Michigan, June 2009</article-title>. <source>MMWR Morb
Mortal Wkly Rep</source>
<year>2009</year>; <volume>58</volume>:
<fpage>749</fpage>&#x02013;<lpage>752</lpage>.<pub-id pub-id-type="pmid">19609249</pub-id></mixed-citation></ref><ref id="bibr37-1358863X20932640"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Avnon</surname><given-names>LS</given-names></name><name><surname>Munteanu</surname><given-names>D</given-names></name><name><surname>Smoliakov</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Thromboembolic events in
patients with severe pandemic influenza A/H1N1</article-title>. <source>Eur
J Intern Med</source>
<year>2015</year>; <volume>26</volume>:
<fpage>596</fpage>&#x02013;<lpage>598</lpage>.<pub-id pub-id-type="pmid">26365372</pub-id></mixed-citation></ref><ref id="bibr38-1358863X20932640"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bunce</surname><given-names>PE</given-names></name><name><surname>High</surname><given-names>SM</given-names></name><name><surname>Nadjafi</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Pandemic H1N1 influenza
infection and vascular thrombosis</article-title>. <source>Clin Infect
Dis</source>
<year>2011</year>; <volume>52</volume>:
<fpage>e14</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">21288835</pub-id></mixed-citation></ref><ref id="bibr39-1358863X20932640"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Obi</surname><given-names>AT</given-names></name><name><surname>Tignanelli</surname><given-names>CJ</given-names></name><name><surname>Jacobs</surname><given-names>BN</given-names></name></person-group>, <etal>et al</etal>
<article-title>Empirical systemic
anticoagulation is associated with decreased venous thromboembolism in
critically ill influenza A H1N1 acute respiratory distress syndrome
patients</article-title>. <source>J Vasc Surg Venous Lymphat Disord</source>
<year>2019</year>; <volume>7</volume>:
<fpage>317</fpage>&#x02013;<lpage>324</lpage>.<pub-id pub-id-type="pmid">30477976</pub-id></mixed-citation></ref><ref id="bibr40-1358863X20932640"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cui</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Prevalence of venous
thromboembolism in patients with severe novel coronavirus
pneumonia</article-title>. <source>J Thromb Haemost</source>. Epub ahead of
print 9 April 2020. DOI: <pub-id pub-id-type="doi">10.1111/jth.14830</pub-id>.</mixed-citation></ref><ref id="bibr41-1358863X20932640"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klok</surname><given-names>FA</given-names></name><name><surname>Kruip</surname><given-names>M</given-names></name><name><surname>van der Meer</surname><given-names>NJM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Incidence of thrombotic
complications in critically ill ICU patients with COVID-19</article-title>.
<source>Thromb Res</source>. Epub ahead of print 10 April 2020. DOI: <pub-id pub-id-type="doi">10.1016/j.thromres.2020.04.013</pub-id>.</mixed-citation></ref><ref id="bibr42-1358863X20932640"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lodigiani</surname><given-names>C</given-names></name><name><surname>Iapichino</surname><given-names>G</given-names></name><name><surname>Carenzo</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Venous and arterial
thromboembolic complications in COVID-19 patients admitted to an academic
hospital in Milan, Italy</article-title>. <source>Thromb Res</source>
<year>2020</year>; <volume>191</volume>:
<fpage>9</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">32353746</pub-id></mixed-citation></ref><ref id="bibr43-1358863X20932640"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oxley</surname><given-names>TJ</given-names></name><name><surname>Mocco</surname><given-names>J</given-names></name><name><surname>Majidi</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Large-vessel stroke as a
presenting feature of Covid-19 in the young</article-title>. <source>N Engl
J Med</source>
<year>2020</year>; <volume>382</volume>: <fpage>e60</fpage>.<pub-id pub-id-type="pmid">32343504</pub-id></mixed-citation></ref><ref id="bibr44-1358863X20932640"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cardiovascular implications
of fatal outcomes of patients with coronavirus disease 2019
(COVID-19)</article-title>. <source>JAMA Cardiol</source>. Epub ahead of
print 27 Mar 2020. DOI: <pub-id pub-id-type="doi">10.1001/jamacardio.2020.1017</pub-id>.</mixed-citation></ref><ref id="bibr45-1358863X20932640"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>
<article-title>Association of cardiac
injury with mortality in hospitalized patients with COVID-19 in Wuhan,
China</article-title>. <source>JAMA Cardiol</source>. Epub ahead of print 25
Mar 2020. DOI: <pub-id pub-id-type="doi">10.1001/jamacardio.2020.0950</pub-id>.</mixed-citation></ref><ref id="bibr46-1358863X20932640"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lacour</surname><given-names>T</given-names></name><name><surname>Semaan</surname><given-names>C</given-names></name><name><surname>Genet</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>Insights for increased risk
of failed fibrinolytic therapy and stent thrombosis associated with COVID-19
in ST-segment elevation myocardial infarction patients</article-title>.
<source>Catheter Cardiovasc Interv</source>. Epub ahead of print 30 April
2020. DOI: <pub-id pub-id-type="doi">10.1002/ccd.28948</pub-id>.</mixed-citation></ref><ref id="bibr47-1358863X20932640"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Corrales-Medina</surname><given-names>VF</given-names></name><name><surname>Madjid</surname><given-names>M</given-names></name><name><surname>Musher</surname><given-names>DM.</given-names></name></person-group>
<article-title>Role of acute infection in triggering acute coronary
syndromes</article-title>. <source>Lancet Infect Dis</source>
<year>2010</year>; <volume>10</volume>:
<fpage>83</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">20113977</pub-id></mixed-citation></ref><ref id="bibr48-1358863X20932640"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Madjid</surname><given-names>M</given-names></name><name><surname>Aboshady</surname><given-names>I</given-names></name><name><surname>Awan</surname><given-names>I</given-names></name></person-group>, <etal>et al</etal>
<article-title>Influenza and cardiovascular
disease: Is there a causal relationship?</article-title>
<source>Tex Heart Inst J</source>
<year>2004</year>; <volume>31</volume>:
<fpage>4</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">15061620</pub-id></mixed-citation></ref><ref id="bibr49-1358863X20932640"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwong</surname><given-names>JC</given-names></name><name><surname>Schwartz</surname><given-names>KL</given-names></name><name><surname>Campitelli</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Acute myocardial infarction
after laboratory-confirmed influenza infection</article-title>. <source>N
Engl J Med</source>
<year>2018</year>; <volume>378</volume>:
<fpage>345</fpage>&#x02013;<lpage>353</lpage>.<pub-id pub-id-type="pmid">29365305</pub-id></mixed-citation></ref><ref id="bibr50-1358863X20932640"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Niu</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Pulmonary pathology of
early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with
lung cancer</article-title>. <source>J Thorac Oncol</source>
<year>2020</year>; <volume>15</volume>:
<fpage>700</fpage>&#x02013;<lpage>704</lpage>.<pub-id pub-id-type="pmid">32114094</pub-id></mixed-citation></ref><ref id="bibr51-1358863X20932640"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Pathological findings of
COVID-19 associated with acute respiratory distress
syndrome</article-title>. <source>Lancet Respir Med</source>
<year>2020</year>; <volume>8</volume>:
<fpage>420</fpage>&#x02013;<lpage>422</lpage>.<pub-id pub-id-type="pmid">32085846</pub-id></mixed-citation></ref><ref id="bibr52-1358863X20932640"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sebag</surname><given-names>SC</given-names></name><name><surname>Bastarache</surname><given-names>JA</given-names></name><name><surname>Ware</surname><given-names>LB.</given-names></name></person-group>
<article-title>Therapeutic modulation of coagulation and fibrinolysis in acute
lung injury and the acute respiratory distress syndrome</article-title>.
<source>Curr Pharm Biotechnol</source>
<year>2011</year>; <volume>12</volume>:
<fpage>1481</fpage>&#x02013;<lpage>1496</lpage>.<pub-id pub-id-type="pmid">21401517</pub-id></mixed-citation></ref><ref id="bibr53-1358863X20932640"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Matthay</surname><given-names>MA.</given-names></name></person-group>
<article-title>Protein C and thrombomodulin in human acute lung
injury</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>
<year>2003</year>; <volume>285</volume>:
<fpage>L514</fpage>&#x02013;<lpage>521</lpage>.<pub-id pub-id-type="pmid">12754194</pub-id></mixed-citation></ref><ref id="bibr54-1358863X20932640"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frantzeskaki</surname><given-names>F</given-names></name><name><surname>Armaganidis</surname><given-names>A</given-names></name><name><surname>Orfanos</surname><given-names>SE.</given-names></name></person-group>
<article-title>Immunothrombosis in acute respiratory distress syndrome: Cross
talks between inflammation and coagulation</article-title>.
<source>Respiration</source>
<year>2017</year>; <volume>93</volume>:
<fpage>212</fpage>&#x02013;<lpage>225</lpage>.<pub-id pub-id-type="pmid">27997925</pub-id></mixed-citation></ref><ref id="bibr55-1358863X20932640"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fox</surname><given-names>SE</given-names></name><name><surname>Akmatbekov</surname><given-names>A</given-names></name><name><surname>Harbert</surname><given-names>JL</given-names></name></person-group>, <etal>et al</etal>
<article-title>Pulmonary and cardiac
pathology in African American patients with COVID-19: An autopsy series from
New Orleans</article-title>. <source>Lancet Respir Med</source>. Epub ahead
of print 27 May 2020. DOI: <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30243-5</pub-id>.</mixed-citation></ref><ref id="bibr56-1358863X20932640"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barnes</surname><given-names>BJ</given-names></name><name><surname>Adrover</surname><given-names>JM</given-names></name><name><surname>Baxter-Stoltzfus</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Targeting potential drivers
of COVID-19: Neutrophil extracellular traps</article-title>. <source>J Exp
Med</source>
<year>2020</year>; <volume>217</volume>:
<fpage>e20200652</fpage>.<pub-id pub-id-type="pmid">32302401</pub-id></mixed-citation></ref><ref id="bibr57-1358863X20932640"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Chi</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Ectonucleotidase
tri(di)phosphohydrolase-1 (ENTPD-1) disrupts inflammasome/interleukin
1beta-driven venous thrombosis</article-title>. <source>J Clin
Invest</source>
<year>2019</year>; <volume>129</volume>:
<fpage>2872</fpage>&#x02013;<lpage>2877</lpage>.<pub-id pub-id-type="pmid">30990798</pub-id></mixed-citation></ref><ref id="bibr58-1358863X20932640"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ali</surname><given-names>RA</given-names></name><name><surname>Gandhi</surname><given-names>AA</given-names></name><name><surname>Meng</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Adenosine receptor agonism
protects against NETosis and thrombosis in antiphospholipid
syndrome</article-title>. <source>Nat Commun</source>
<year>2019</year>; <volume>10</volume>: <year>1916</year>.</mixed-citation></ref><ref id="bibr59-1358863X20932640"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kambas</surname><given-names>K</given-names></name><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Ritis</surname><given-names>K.</given-names></name></person-group>
<article-title>The emerging role of neutrophils in thrombosis&#x02014;The journey of TF
through NETs</article-title>. <source>Front Immunol</source>
<year>2012</year>; <volume>3</volume>: <fpage>385</fpage>.<pub-id pub-id-type="pmid">23264778</pub-id></mixed-citation></ref><ref id="bibr60-1358863X20932640"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liberale</surname><given-names>L</given-names></name><name><surname>Holy</surname><given-names>EW</given-names></name><name><surname>Akhmedov</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Interleukin-1&#x003b2; mediates
arterial thrombus formation via NET-associated tissue
factor</article-title>. <source>J Clin Med</source>
<year>2019</year>; <volume>8</volume>: <year>2072</year>.</mixed-citation></ref><ref id="bibr61-1358863X20932640"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noubouossie</surname><given-names>DF</given-names></name><name><surname>Reeves</surname><given-names>BN</given-names></name><name><surname>Strahl</surname><given-names>BD</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neutrophils: Back in the
thrombosis spotlight</article-title>. <source>Blood</source>
<year>2019</year>; <volume>133</volume>:
<fpage>2186</fpage>&#x02013;<lpage>2197</lpage>.<pub-id pub-id-type="pmid">30898858</pub-id></mixed-citation></ref><ref id="bibr62-1358863X20932640"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thalin</surname><given-names>C</given-names></name><name><surname>Hisada</surname><given-names>Y</given-names></name><name><surname>Lundstrom</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neutrophil extracellular
traps: Villains and targets in arterial, venous, and cancer-associated
thrombosis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>
<year>2019</year>; <volume>39</volume>:
<fpage>1724</fpage>&#x02013;<lpage>1738</lpage>.<pub-id pub-id-type="pmid">31315434</pub-id></mixed-citation></ref><ref id="bibr63-1358863X20932640"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Yalavarthi</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neutrophil extracellular
traps in COVID-19</article-title>. <source>JCI Insight</source>. Epub ahead
of print 24 April 2020. DOI: <pub-id pub-id-type="doi">10.1172/jci.insight.138999</pub-id>.</mixed-citation></ref><ref id="bibr64-1358863X20932640"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Zuo</surname><given-names>M</given-names></name><name><surname>Yalavarthi</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neutrophil extracellular
traps and thrombosis in COVID-19</article-title>. <source>medRxiv</source>.
Preprint 5 May 2020. DOI: <pub-id pub-id-type="doi">10.1101/2020.04.30.20086736</pub-id>.</mixed-citation></ref><ref id="bibr65-1358863X20932640"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bone</surname><given-names>RC</given-names></name><name><surname>Francis</surname><given-names>PB</given-names></name><name><surname>Pierce</surname><given-names>AK.</given-names></name></person-group>
<article-title>Intravascular coagulation associated with the adult respiratory
distress syndrome</article-title>. <source>Am J Med</source>
<year>1976</year>; <volume>61</volume>:
<fpage>585</fpage>&#x02013;<lpage>589</lpage>.<pub-id pub-id-type="pmid">984062</pub-id></mixed-citation></ref><ref id="bibr66-1358863X20932640"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blondonnet</surname><given-names>R</given-names></name><name><surname>Constantin</surname><given-names>JM</given-names></name><name><surname>Sapin</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>
<article-title>A pathophysiologic approach
to biomarkers in acute respiratory distress syndrome</article-title>.
<source>Dis Markers</source>
<year>2016</year>; <volume>2016</volume>:
<fpage>3501373</fpage>.<pub-id pub-id-type="pmid">26980924</pub-id></mixed-citation></ref><ref id="bibr67-1358863X20932640"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haynes</surname><given-names>JB</given-names></name><name><surname>Hyers</surname><given-names>TM</given-names></name><name><surname>Giclas</surname><given-names>PC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Elevated fibrin(ogen)
degradation products in the adult respiratory distress
syndrome</article-title>. <source>Am Rev Respir Dis</source>
<year>1980</year>; <volume>122</volume>:
<fpage>841</fpage>&#x02013;<lpage>847</lpage>.<pub-id pub-id-type="pmid">6450559</pub-id></mixed-citation></ref><ref id="bibr68-1358863X20932640"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sapru</surname><given-names>A</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name><name><surname>Liu</surname><given-names>KD</given-names></name></person-group>, <etal>et al</etal>
<article-title>Plasma soluble
thrombomodulin levels are associated with mortality in the acute respiratory
distress syndrome</article-title>. <source>Int Care Med</source>
<year>2015</year>; <volume>41</volume>:
<fpage>470</fpage>&#x02013;<lpage>478</lpage>.</mixed-citation></ref><ref id="bibr69-1358863X20932640"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Parsons</surname><given-names>PE</given-names></name></person-group>, <etal>et al</etal>
<article-title>Pathogenetic and prognostic
significance of altered coagulation and fibrinolysis in acute lung
injury/acute respiratory distress syndrome</article-title>. <source>Crit
Care Med</source>
<year>2007</year>; <volume>35</volume>:
<fpage>1821</fpage>&#x02013;<lpage>1828</lpage>.<pub-id pub-id-type="pmid">17667242</pub-id></mixed-citation></ref><ref id="bibr70-1358863X20932640"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Chambers</surname><given-names>RC</given-names></name><name><surname>Liu</surname><given-names>KD.</given-names></name></person-group>
<article-title>Acute respiratory distress syndrome</article-title>. <source>N
Engl J Med</source>
<year>2017</year>; <volume>377</volume>:
<fpage>1904</fpage>&#x02013;<lpage>1905</lpage>.</mixed-citation></ref><ref id="bibr71-1358863X20932640"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prabhakaran</surname><given-names>P</given-names></name><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>White</surname><given-names>KE</given-names></name></person-group>, <etal>et al</etal>
<article-title>Elevated levels of
plasminogen activator inhibitor-1 in pulmonary edema fluid are associated
with mortality in acute lung injury</article-title>. <source>Am J Physiol
Lung Cell Mol Physiol</source>
<year>2003</year>; <volume>285</volume>:
<fpage>L20</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">12730079</pub-id></mixed-citation></ref><ref id="bibr72-1358863X20932640"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Zhuo</surname><given-names>H</given-names></name><name><surname>Brady</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Pathogenetic and predictive
value of biomarkers in patients with ALI and lower severity of illness:
Results from two clinical trials</article-title>. <source>Am J Physiol Lung
Cell Mol Physiol</source>
<year>2012</year>; <volume>303</volume>:
<fpage>L634</fpage>&#x02013;<lpage>639</lpage>.<pub-id pub-id-type="pmid">22865551</pub-id></mixed-citation></ref><ref id="bibr73-1358863X20932640"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bastarache</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Geiser</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal>
<article-title>The alveolar epithelium can
initiate the extrinsic coagulation cascade through expression of tissue
factor</article-title>. <source>Thorax</source>
<year>2007</year>; <volume>62</volume>:
<fpage>608</fpage>&#x02013;<lpage>616</lpage>.<pub-id pub-id-type="pmid">17356058</pub-id></mixed-citation></ref><ref id="bibr74-1358863X20932640"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bach-Gansmo</surname><given-names>ET</given-names></name><name><surname>Halvorsen</surname><given-names>S</given-names></name><name><surname>Godal</surname><given-names>HC</given-names></name></person-group>, <etal>et al</etal>
<article-title>D-dimers are degraded by
human neutrophil elastase</article-title>. <source>Thromb Res</source>
<year>1996</year>; <volume>82</volume>:
<fpage>177</fpage>&#x02013;<lpage>186</lpage>.<pub-id pub-id-type="pmid">9163071</pub-id></mixed-citation></ref><ref id="bibr75-1358863X20932640"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gando</surname><given-names>S</given-names></name><name><surname>Hayakawa</surname><given-names>M</given-names></name><name><surname>Sawamura</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>The activation of neutrophil
elastase-mediated fibrinolysis is not sufficient to overcome the
fibrinolytic shutdown of disseminated intravascular coagulation associated
with systemic inflammation</article-title>. <source>Thromb Res</source>
<year>2007</year>; <volume>121</volume>:
<fpage>67</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">17397908</pub-id></mixed-citation></ref><ref id="bibr76-1358863X20932640"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koupenova</surname><given-names>M</given-names></name><name><surname>Clancy</surname><given-names>L</given-names></name><name><surname>Corkrey</surname><given-names>HA</given-names></name></person-group>, <etal>et al</etal>
<article-title>Circulating platelets as
mediators of immunity, inflammation, and thrombosis</article-title>.
<source>Circ Res</source>
<year>2018</year>; <volume>122</volume>:
<fpage>337</fpage>&#x02013;<lpage>351</lpage>.<pub-id pub-id-type="pmid">29348254</pub-id></mixed-citation></ref><ref id="bibr77-1358863X20932640"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mackman</surname><given-names>N.</given-names></name></person-group>
<article-title>The many faces of tissue factor</article-title>. <source>J Thromb
Haemost</source>
<year>2009</year>; <volume>7</volume>(<issue>suppl 1</issue>):
<fpage>136</fpage>&#x02013;<lpage>139</lpage>.<pub-id pub-id-type="pmid">19630786</pub-id></mixed-citation></ref><ref id="bibr78-1358863X20932640"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>JC.</given-names></name></person-group>
<article-title>Acute respiratory distress syndrome as an organ phenotype of
vascular microthrombotic disease: Based on hemostatic theory and endothelial
molecular pathogenesis</article-title>. <source>Clin Appl Thromb
Hemost</source>
<year>2019</year>; <volume>25</volume>:
<fpage>1076029619887437</fpage>.<pub-id pub-id-type="pmid">31775524</pub-id></mixed-citation></ref><ref id="bibr79-1358863X20932640"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van der Poll</surname><given-names>T</given-names></name><name><surname>Herwald</surname><given-names>H</given-names></name></person-group>
<article-title>The coagulation system and its function in early
immune defense</article-title>. <source>Thromb Haemost</source>
<year>2014</year>; <volume>112</volume>:
<fpage>640</fpage>&#x02013;<lpage>648</lpage>.<pub-id pub-id-type="pmid">24696161</pub-id></mixed-citation></ref><ref id="bibr80-1358863X20932640"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lefrancais</surname><given-names>E</given-names></name><name><surname>Mallavia</surname><given-names>B</given-names></name><name><surname>Zhuo</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Maladaptive role of
neutrophil extracellular traps in pathogen-induced lung
injury</article-title>. <source>JCI Insight</source>
<year>2018</year>; <volume>3</volume>: <fpage>e98178</fpage>.</mixed-citation></ref><ref id="bibr81-1358863X20932640"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glas</surname><given-names>GJ</given-names></name><name><surname>Van Der Sluijs</surname><given-names>KF</given-names></name><name><surname>Schultz</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Bronchoalveolar hemostasis
in lung injury and acute respiratory distress syndrome</article-title>.
<source>J Thromb Haemost</source>
<year>2013</year>; <volume>11</volume>:
<fpage>17</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">23114008</pub-id></mixed-citation></ref><ref id="bibr82-1358863X20932640"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tomashefski</surname><given-names>JF</given-names><suffix>Jr.</suffix></name></person-group>
<article-title>Pulmonary pathology of acute respiratory distress
syndrome</article-title>. <source>Clin Chest Med</source>
<year>2000</year>; <volume>21</volume>:
<fpage>435</fpage>&#x02013;<lpage>466</lpage>.<pub-id pub-id-type="pmid">11019719</pub-id></mixed-citation></ref><ref id="bibr83-1358863X20932640"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vesconi</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>GP</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Pulmonary microthrombosis in
severe adult respiratory distress syndrome</article-title>. <source>Crit
Care Med</source>
<year>1988</year>; <volume>16</volume>:
<fpage>111</fpage>&#x02013;<lpage>113</lpage>.<pub-id pub-id-type="pmid">3342622</pub-id></mixed-citation></ref><ref id="bibr84-1358863X20932640"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Receptor-binding domain of
SARS-CoV spike protein induces highly potent neutralizing antibodies:
Implication for developing subunit vaccine</article-title>. <source>Biochem
Biophys Res Commun</source>
<year>2004</year>; <volume>324</volume>:
<fpage>773</fpage>&#x02013;<lpage>781</lpage>.<pub-id pub-id-type="pmid">15474494</pub-id></mixed-citation></ref><ref id="bibr85-1358863X20932640"><label>85</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Greenough</surname><given-names>TC</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Efficient replication of
severe acute respiratory syndrome coronavirus in mouse cells is limited by
murine angiotensin-converting enzyme 2</article-title>. <source>J
Virol</source>
<year>2004</year>; <volume>78</volume>:
<fpage>11429</fpage>&#x02013;<lpage>11433</lpage>.<pub-id pub-id-type="pmid">15452268</pub-id></mixed-citation></ref><ref id="bibr86-1358863X20932640"><label>86</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Vasilieva</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>Angiotensin-converting
enzyme 2 is a functional receptor for the SARS coronavirus</article-title>.
<source>Nature</source>
<year>2003</year>; <volume>426</volume>:
<fpage>450</fpage>&#x02013;<lpage>454</lpage>.<pub-id pub-id-type="pmid">14647384</pub-id></mixed-citation></ref><ref id="bibr87-1358863X20932640"><label>87</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Chakraborti</surname><given-names>S</given-names></name><name><surname>Dimitrov</surname><given-names>AS</given-names></name></person-group>, <etal>et al</etal>
<article-title>The SARS-CoV S glycoprotein:
Expression and functional characterization</article-title>. <source>Biochem
Biophys Res Commun</source>
<year>2003</year>; <volume>312</volume>:
<fpage>1159</fpage>&#x02013;<lpage>1164</lpage>.<pub-id pub-id-type="pmid">14651994</pub-id></mixed-citation></ref><ref id="bibr88-1358863X20932640"><label>88</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>SARS-CoV-2 cell entry
depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease
inhibitor</article-title>. <source>Cell</source>
<year>2020</year>; <volume>181</volume>: 271&#x02013;280.e8.</mixed-citation></ref><ref id="bibr89-1358863X20932640"><label>89</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Corbett</surname><given-names>KS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Cryo-EM structure of the
2019-nCoV spike in the prefusion conformation</article-title>.
<source>Science</source>
<year>2020</year>; <volume>367</volume>:
<fpage>1260</fpage>&#x02013;<lpage>1263</lpage>.<pub-id pub-id-type="pmid">32075877</pub-id></mixed-citation></ref><ref id="bibr90-1358863X20932640"><label>90</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group>, <etal>et al</etal>
<article-title>Expression of elevated
levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in
SARS patients: Relation to the acute lung injury and pathogenesis of
SARS</article-title>. <source>J Pathol</source>
<year>2006</year>; <volume>210</volume>:
<fpage>288</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">17031779</pub-id></mixed-citation></ref><ref id="bibr91-1358863X20932640"><label>91</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varga</surname><given-names>Z</given-names></name><name><surname>Flammer</surname><given-names>AJ</given-names></name><name><surname>Steiger</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>
<article-title>Endothelial cell infection
and endotheliitis in COVID-19</article-title>. <source>Lancet</source>
<year>2020</year>; <volume>395</volume>:
<fpage>1417</fpage>&#x02013;<lpage>1418</lpage>.<pub-id pub-id-type="pmid">32325026</pub-id></mixed-citation></ref><ref id="bibr92-1358863X20932640"><label>92</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Bankhead</surname><given-names>A</given-names><suffix>3rd</suffix></name><name><surname>Jeng</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Mechanisms of severe acute
respiratory syndrome coronavirus-induced acute lung injury</article-title>.
<source>mBio</source>
<year>2013</year>; <volume>4</volume>:
<fpage>e00271</fpage>-13.<pub-id pub-id-type="pmid">23919993</pub-id></mixed-citation></ref><ref id="bibr93-1358863X20932640"><label>93</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berri</surname><given-names>F</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><name><surname>Hanss</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Plasminogen controls
inflammation and pathogenesis of influenza virus infections via
fibrinolysis</article-title>. <source>PLoS Pathog</source>
<year>2013</year>; <volume>9</volume>: <fpage>e1003229</fpage>.<pub-id pub-id-type="pmid">23555246</pub-id></mixed-citation></ref><ref id="bibr94-1358863X20932640"><label>94</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ji</surname><given-names>HL</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Matalon</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Elevated plasmin(ogen) as a
common risk factor for COVID-19 susceptibility</article-title>.
<source>Physiol Rev</source>
<year>2020</year>; <volume>100</volume>:
<fpage>1065</fpage>&#x02013;<lpage>1075</lpage>.<pub-id pub-id-type="pmid">32216698</pub-id></mixed-citation></ref><ref id="bibr95-1358863X20932640"><label>95</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jaimes</surname><given-names>F</given-names></name><name><surname>De La Rosa</surname><given-names>G</given-names></name><name><surname>Morales</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Unfractioned heparin for
treatment of sepsis: A randomized clinical trial (The HETRASE
Study)</article-title>. <source>Crit Care Med</source>
<year>2009</year>; <volume>37</volume>:
<fpage>1185</fpage>&#x02013;<lpage>1196</lpage>.<pub-id pub-id-type="pmid">19242322</pub-id></mixed-citation></ref><ref id="bibr96-1358863X20932640"><label>96</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abraham</surname><given-names>E</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Gutierrez</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Double-blind randomised
controlled trial of monoclonal antibody to human tumour necrosis factor in
treatment of septic shock. NORASEPT II Study Group</article-title>.
<source>Lancet</source>
<year>1998</year>; <volume>351</volume>:
<fpage>929</fpage>&#x02013;<lpage>933</lpage>.<pub-id pub-id-type="pmid">9734938</pub-id></mixed-citation></ref><ref id="bibr97-1358863X20932640"><label>97</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abraham</surname><given-names>E</given-names></name><name><surname>Wunderink</surname><given-names>R</given-names></name><name><surname>Silverman</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Efficacy and safety of
monoclonal antibody to human tumor necrosis factor alpha in patients with
sepsis syndrome. A randomized, controlled, double-blind, multicenter
clinical trial. TNF-alpha MAb Sepsis Study Group</article-title>.
<source>JAMA</source>
<year>1995</year>; <volume>273</volume>:
<fpage>934</fpage>&#x02013;<lpage>941</lpage>.<pub-id pub-id-type="pmid">7884952</pub-id></mixed-citation></ref><ref id="bibr98-1358863X20932640"><label>98</label><mixed-citation publication-type="journal">
<collab>National Heart, Lung, and Blood Institute ARDS Clinical Trials
Network</collab>, <person-group person-group-type="author"><name><surname>Truwit</surname><given-names>JD</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name></person-group>, <etal>et al</etal>
<article-title>Rosuvastatin for
sepsis-associated acute respiratory distress syndrome</article-title>.
<source>N Engl J Med</source>
<year>2014</year>; <volume>370</volume>:
<fpage>2191</fpage>&#x02013;<lpage>2200</lpage>.<pub-id pub-id-type="pmid">24835849</pub-id></mixed-citation></ref><ref id="bibr99-1358863X20932640"><label>99</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Wheeler</surname><given-names>AP</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name></person-group>, <etal>et al</etal>
<article-title>The effects of ibuprofen on
the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis
Study Group</article-title>. <source>N Engl J Med</source>
<year>1997</year>; <volume>336</volume>:
<fpage>912</fpage>&#x02013;<lpage>918</lpage>.<pub-id pub-id-type="pmid">9070471</pub-id></mixed-citation></ref><ref id="bibr100-1358863X20932640"><label>100</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>KP</given-names></name><name><surname>Hudson</surname><given-names>LD</given-names></name><name><surname>Goodman</surname><given-names>RB</given-names></name></person-group>, <etal>et al</etal>
<article-title>Efficacy and safety of
corticosteroids for persistent acute respiratory distress
syndrome</article-title>. <source>N Engl J Med</source>
<year>2006</year>; <volume>354</volume>:
<fpage>1671</fpage>&#x02013;<lpage>1684</lpage>.<pub-id pub-id-type="pmid">16625008</pub-id></mixed-citation></ref><ref id="bibr101-1358863X20932640"><label>101</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Anticoagulant treatment is
associated with decreased mortality in severe coronavirus disease 2019
patients with coagulopathy</article-title>. <source>J Thromb
Haemost</source>
<year>2020</year>; <volume>18</volume>:
<fpage>1094</fpage>&#x02013;<lpage>1099</lpage>.<pub-id pub-id-type="pmid">32220112</pub-id></mixed-citation></ref><ref id="bibr102-1358863X20932640"><label>102</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thachil</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Gando</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>ISTH interim guidance on
recognition and management of coagulopathy in COVID-19</article-title>.
<source>J Thromb Haemost</source>
<year>2020</year>; <volume>18</volume>:
<fpage>1023</fpage>&#x02013;<lpage>1026</lpage>.<pub-id pub-id-type="pmid">32338827</pub-id></mixed-citation></ref><ref id="bibr103-1358863X20932640"><label>103</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bikdeli</surname><given-names>B</given-names></name><name><surname>Madhavan</surname><given-names>MV</given-names></name><name><surname>Jimenez</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>COVID-19 and thrombotic or
thromboembolic disease: Implications for prevention, antithrombotic therapy,
and follow-up</article-title>. <source>J Am Coll Cardiol</source>
<year>2020</year>; S0735-1097(20): 35008-7.</mixed-citation></ref><ref id="bibr104-1358863X20932640"><label>104</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen</surname><given-names>AT</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Goldhaber</surname><given-names>SZ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Extended thromboprophylaxis
with betrixaban in acutely ill medical patients</article-title>. <source>N
Engl J Med</source>
<year>2016</year>; <volume>375</volume>:
<fpage>534</fpage>&#x02013;<lpage>544</lpage>.<pub-id pub-id-type="pmid">27232649</pub-id></mixed-citation></ref><ref id="bibr105-1358863X20932640"><label>105</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen</surname><given-names>AT</given-names></name><name><surname>Spiro</surname><given-names>TE</given-names></name><name><surname>Spyropoulos</surname><given-names>AC</given-names></name></person-group>; <collab>MAGELLAN Steering Committee</collab>.
<article-title>Rivaroxaban for thromboprophylaxis in acutely ill medical
patients</article-title>. <source>N Engl J Med</source>
<year>2013</year>; <volume>368</volume>:
<fpage>1945</fpage>&#x02013;<lpage>1946</lpage>.</mixed-citation></ref><ref id="bibr106-1358863X20932640"><label>106</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dentali</surname><given-names>F</given-names></name><name><surname>Mumoli</surname><given-names>N</given-names></name><name><surname>Prisco</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Efficacy and safety of
extended thromboprophylaxis for medically ill patients. A meta-analysis of
randomised controlled trials</article-title>. <source>Thromb
Haemost</source>
<year>2017</year>; <volume>117</volume>:
<fpage>606</fpage>&#x02013;<lpage>617</lpage>.<pub-id pub-id-type="pmid">28078350</pub-id></mixed-citation></ref><ref id="bibr107-1358863X20932640"><label>107</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Fuller</surname><given-names>HD</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name></person-group>, <etal>et al</etal>
<article-title>Risk factors for
gastrointestinal bleeding in critically ill patients. Canadian Critical Care
Trials Group</article-title>. <source>N Engl J Med</source>
<year>1994</year>; <volume>330</volume>:
<fpage>377</fpage>&#x02013;<lpage>381</lpage>.<pub-id pub-id-type="pmid">8284001</pub-id></mixed-citation></ref><ref id="bibr108-1358863X20932640"><label>108</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paranjpe</surname><given-names>I</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Lala</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Association of treatment
dose anticoagulation with in-hospital survival among hospitalized patients
with COVID-19</article-title>. <source>J Am Coll Cardiol</source>
<year>2020</year>; S0735-1097(20): 35218-9.</mixed-citation></ref><ref id="bibr109-1358863X20932640"><label>109</label><mixed-citation publication-type="book">
<collab>Persantine (dipyridamole) [package insert].</collab>
<publisher-loc>Ridgefield, CT</publisher-loc>: <publisher-name>Boehringer
Ingelheim Pharmaceuticals, Inc.</publisher-name>
<month>12</month>
<year>2019</year>.</mixed-citation></ref><ref id="bibr110-1358863X20932640"><label>110</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macatangay</surname><given-names>BJC</given-names></name><name><surname>Jackson</surname><given-names>EK</given-names></name><name><surname>Abebe</surname><given-names>KZ</given-names></name></person-group>, <etal>et al</etal>
<article-title>A randomized,
placebo-controlled, pilot clinical trial of dipyridamole to decrease
HIV-associated chronic inflammation</article-title>. <source>J Infect
Dis</source>
<year>2020</year>; <volume>221</volume>:
<fpage>1598</fpage>&#x02013;<lpage>1606</lpage>.<pub-id pub-id-type="pmid">31282542</pub-id></mixed-citation></ref><ref id="bibr111-1358863X20932640"><label>111</label><mixed-citation publication-type="web">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Y-Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>FEP-based screening prompts
drug repositioning against COVID-19</article-title>.
<source>bioRxiv</source>. Preprint 25 March 2020. DOI: <pub-id pub-id-type="doi">10.1101/2020.03.23.004580</pub-id>.</mixed-citation></ref><ref id="bibr112-1358863X20932640"><label>112</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galabov</surname><given-names>AS</given-names></name><name><surname>Mastikova</surname><given-names>M.</given-names></name></person-group>
<article-title>Dipyridamole induces interferon in man</article-title>.
<source>Biomed Pharmacother</source>. <year>1984</year>;
<volume>38</volume>: <fpage>412</fpage>&#x02013;<lpage>413</lpage>.<pub-id pub-id-type="pmid">6084526</pub-id></mixed-citation></ref><ref id="bibr113-1358863X20932640"><label>113</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Potential therapeutic
effects of dipyridamole in the severely ill patients with
COVID-19</article-title>. <source>Acta Pharm Sin B</source>. Epub ahead of
print 20 April 2020. DOI: <pub-id pub-id-type="doi">10.1016/j.apsb.2020.04.008</pub-id>.</mixed-citation></ref></ref-list></back></article>